Who are Roactemra's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tocilizumab or sarilumab, Ro-Actemra, MIL62, Placebo to GSK3196165/ Sarilumab, EU-approved RoActemra, Actemra(EU-licensed).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/tocilizumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Roactemra — Competitive Intelligence Brief

Roactemra (tocilizumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Interleukin-6 Receptor Antagonist [EPC]. Area: Oncology.

marketed Interleukin-6 Receptor Antagonist [EPC] Interleukin-6 receptor Oncology Monoclonal antibody Live · refreshed every 30 min

Target snapshot

Roactemra (tocilizumab) — Roche. Roactemra works by blocking the interleukin-6 receptor, a protein that plays a key role in inflammation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Roactemra TARGET	tocilizumab	Roche	marketed	Interleukin-6 Receptor Antagonist [EPC]	Interleukin-6 receptor	2010-01-01
tocilizumab or sarilumab	tocilizumab-or-sarilumab	Pfizer	marketed	monoclonal antibody	interleukin-6 receptor
Ro-Actemra	Ro-Actemra	Medical University of Vienna	marketed	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
MIL62	MIL62	Beijing Mabworks Biotech Co., Ltd.	phase 3	IL-6 receptor antagonist monoclonal antibody	IL-6R (Interleukin-6 receptor)
Placebo to GSK3196165/ Sarilumab	Placebo to GSK3196165/ Sarilumab	GlaxoSmithKline	phase 3	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)
EU-approved RoActemra	EU-approved RoActemra	Fresenius Kabi SwissBioSim GmbH	phase 3	IL-6 receptor antagonist (monoclonal antibody)	IL-6R (Interleukin-6 receptor)
Actemra(EU-licensed)	Actemra(EU-licensed)	Bio-Thera Solutions	phase 3	IL-6 receptor antagonist	IL-6R (Interleukin-6 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Interleukin-6 Receptor Antagonist [EPC] class)

· 2 drugs in this class
BIOGEN MA · 1 drug in this class
CELLTRION INC · 1 drug in this class
FRESENIUS KABI USA · 1 drug in this class
Roche · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Roactemra — Competitive Intelligence Brief. https://druglandscape.com/ci/tocilizumab. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab